Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Birth Control Methods01:22

Birth Control Methods

5.6K
Vasectomy is a surgical form of male sterilization that involves severing and sealing the vasa deferentia, preventing sperm from mixing with semen during ejaculation. Because a vasectomy does not impact the testes' ability to produce testosterone, hormone levels, libido, and sexual function generally remain unchanged. While vasectomy is highly effective in preventing pregnancy, with a success rate near 99.85%, rare cases of recanalization (spontaneous reconnection) can occur. Although...
5.6K
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

139
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
139
Modified-Release Drug Delivery Systems: Stimuli-Activated01:30

Modified-Release Drug Delivery Systems: Stimuli-Activated

184
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
184
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

319
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
319
Transdermal Drug Delivery Systems01:18

Transdermal Drug Delivery Systems

238
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
238
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

169
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
169

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bevacizumab added to conventional induction chemotherapy for children with high risk neuroblastoma (BRAVEN trial).

Discover oncology·2026
Same author

Saroglitazar, a novel PPAR-α/γ agonist, modulates thyroid hormone homeostasis through hepatic UGT expression in wistar rats.

Chemico-biological interactions·2026
Same author

How the Stakeholders' Perception Contributes to the Pharmaceutical Strategies: A Regional Case Study in Latin America.

Journal of market access & health policy·2025
Same author

To the Editor, "CEBPE-Related Immunodeficiency Mimicking Acute Myeloid Leukemia: A Diagnostic Pitfall in Pediatric Autoinflammatory Disease".

Journal of clinical immunology·2025
Same author

Integrating immune adverse outcome pathways into vaccine safety evaluation.

Archives of toxicology·2025
Same author

Abnormal Vaginal Microbiota Associated with miRNA Targeting the HIV-Host Interactome.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: May 6, 2026

Alternating Magnetic Field-Responsive Hybrid Gelatin Microgels for Controlled Drug Release
09:11

Alternating Magnetic Field-Responsive Hybrid Gelatin Microgels for Controlled Drug Release

Published on: February 13, 2016

10.2K

Bioresponsive Hydrogel for On-Demand Nonhormonal Contraception.

Giovanni M Pauletti1, Pankaj Dwivedi1, Ping Li2

  • 1Department of Pharmaceutical and Administrative Sciences, St. Louis College of Pharmacy, University of Health Sciences and Pharmacy in St. Louis, St. Louis, MO 63110, USA.

Gels (Basel, Switzerland)
|November 26, 2025
PubMed
Summary

A novel bioresponsive hydrogel (CP4%/PVP4%) enhances contraceptive barriers by reacting to seminal fluid. This drug-free hydrogel significantly reduces sperm motility and migration, offering a safe and effective barrier for pregnancy prevention.

Keywords:
drug-freefemale-initiatedpartner-independentphysical contraceptive barrier

More Related Videos

Fabricating Degradable Thermoresponsive Hydrogels on Multiple Length Scales via Reactive Extrusion, Microfluidics, Self-assembly, and Electrospinning
12:07

Fabricating Degradable Thermoresponsive Hydrogels on Multiple Length Scales via Reactive Extrusion, Microfluidics, Self-assembly, and Electrospinning

Published on: April 16, 2018

14.0K
Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications
09:39

Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications

Published on: February 7, 2021

8.7K

Related Experiment Videos

Last Updated: May 6, 2026

Alternating Magnetic Field-Responsive Hybrid Gelatin Microgels for Controlled Drug Release
09:11

Alternating Magnetic Field-Responsive Hybrid Gelatin Microgels for Controlled Drug Release

Published on: February 13, 2016

10.2K
Fabricating Degradable Thermoresponsive Hydrogels on Multiple Length Scales via Reactive Extrusion, Microfluidics, Self-assembly, and Electrospinning
12:07

Fabricating Degradable Thermoresponsive Hydrogels on Multiple Length Scales via Reactive Extrusion, Microfluidics, Self-assembly, and Electrospinning

Published on: April 16, 2018

14.0K
Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications
09:39

Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications

Published on: February 7, 2021

8.7K

Area of Science:

  • Biomaterials Science
  • Reproductive Biology
  • Drug Delivery Systems

Background:

  • Bioresponsive hydrogels offer tunable properties for therapeutic applications.
  • Existing contraceptive methods have limitations, driving the need for innovative solutions.
  • Fortifying natural contraceptive barriers presents a promising drug-free approach.

Purpose of the Study:

  • To investigate a bioresponsive hydrogel (CP4%/PVP4%) as a drug-free contraceptive barrier.
  • To assess the hydrogel's structural changes in response to seminal fluid.
  • To evaluate the hydrogel's efficacy in reducing sperm motility and migration.

Main Methods:

  • Formulation of a hydrogel with Carbopol® 974P and polyvinylpyrrolidone (CP4%/PVP4%).
  • Exposure of the hydrogel to simulated seminal fluid (pH 7.7) and human semen.
  • In vitro assessment of sperm migration and motility.
  • In vitro and in vivo safety evaluations.
  • Exploratory in vivo study in rabbits comparing efficacy to a marketed product.

Main Results:

  • CP4%/PVP4% hydrogel exhibited bioresponsive structural changes upon exposure to simulated seminal fluid.
  • Combination with human semen reduced in vitro sperm migration by 97% and motility to below fertility criteria.
  • In vitro and in vivo safety assessments demonstrated a favorable profile.
  • The hydrogel showed comparable in vivo pregnancy prevention efficacy to VCF® Gel in rabbits.

Conclusions:

  • The bioresponsive CP4%/PVP4% hydrogel acts as an effective drug-free contraceptive barrier.
  • The hydrogel's mechanism involves structural changes that impede sperm function upon contact with semen.
  • This hydrogel presents a promising, safe, and effective alternative for on-demand contraception.